1-2 of 2
Kathleen Kelly
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor

Remi Adelaiye-Ogala, Berkley E. Gryder, Yen Thi Minh Nguyen, Aian Neil Alilin, Adlai R. Grayson, Wardah Bajwa, Keith H. Jansson, Michael L. Beshiri, Supreet Agarwal, Jose Antonio Rodriguez-Nieves, Brian Capaldo, Kathleen Kelly, David J. VanderWeele
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (7): 1436–1447.
https://doi.org/10.1158/1535-7163.MCT-19-0936
Published: 02 July 2020
View article titled, Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor
Open the PDF for Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor in another window
Includes: Supplementary data
Journal Articles

Abstract C112: Cabozantinib eradicates advanced murine prostate cancer by activating anti-tumor innate immunity

Akash Patnaik, Kenneth Swanson, Sabina Signoretti, Huihui Ye, Eva Csizmadia, Jesse Novak, Marina Gehring, Katja Helenius, Athalia Pyzer, Laleh Montaser, Lily Wang, Olivier Elemento, Elena Levantini, John Clohessy, John Asara, Kathleen Kelly, Pier Paolo Pandolfi, Jacalyn Rosenblatt, David Avigan, Steven Balk, Lewis Cantley
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C112.
https://doi.org/10.1158/1535-7163.TARG-15-C112
Published: 01 December 2015
View article titled, Abstract C112: Cabozantinib eradicates advanced murine prostate cancer by activating anti-tumor innate immunity